Nyxoah Archives | Be Korea-savvy
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in England, marked [...]

Information on the Total Number of Voting Rights And Shares: Nyxoah

Information on the Total Number of Voting Rights And Shares: Nyxoah

Mont-Saint-Guibert, Belgium, Nov. 27 (Korea Bizwire) – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,429,682.56 Total number of securities carrying voting rights: 37,427,265 (all ordinary shares) Total number of [...]

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference Mont-Saint-Guibert, Belgium, Nov. 20 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36th Annual Healthcare Conference [...]

Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024: Nyxoah

Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024: Nyxoah

REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities [...]

Publication Relating to Transparency Notifications: Nyxoah

Publication Relating to Transparency Notifications: Nyxoah

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert, Belgium, Nov. 18 (Korea Bizwire) – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following [...]

Nyxoah Reports Third Quarter Financial and Operating Results

Nyxoah Reports Third Quarter Financial and Operating Results

REGULATED INFORMATION  Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium, Nov. 6 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2024. Recent Financial and Operating Highlights Presented compelling DREAM data results at International Surgical Sleep Society in September. Raised €24.6 million through an ATM program [...]

Nyxoah Appoints John Landry as Chief Financial Officer

Nyxoah Appoints John Landry as Chief Financial Officer

Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium, Nov. 4 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John [...]

Publication relating to transparency notifications: Nyxoah

Publication relating to transparency notifications: Nyxoah

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 23, 2024, Nyxoah [...]

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium, Oct. 22 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for [...]

Publication Relating to Transparency Notifications

Publication Relating to Transparency Notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), Oct.15 (Korea Bizwire) – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received three transparency notifications as detailed below. Jürgen Hambrecht On October 15, 2024, Nyxoah received a transparency notification from Jürgen Hambrecht [...]